Obliterative portal venopathy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{SI}}
{{SI}}
Hepatoportal sclerosis (HPS) is a rare disorder characterized by sclerosis of the intrahepatic portal veins, non-cirrhotic portal hypertension, asymptomatic splenomegaly and recurrent variceal bleeding. Prevalence is unknown. Distribution is worldwide, with many cases reported in Asia. The disease may occur at any age. Both sexes are equally affected. HPS typically manifests with overt splenomegaly with pancytopenia, portal hypertension and mild abnormalities in liver function tests. HPS patients are in good condition, but may present with ruptured esophagogastric varices. Most commonly, the condition is detected in investigating a fortuitous finding of hypersplenism or splenomegaly. Ascites, hepatic encephalopathy and jaundice are uncommon. Main histopathologic findings are periportal fibrosis, occlusion of small portal veins, sclerosis of the portal venous system, and proliferation of small vascular channels within/around portal tracts. The disease is slowly progressive. Liver failure, ascites or encephalopathy may occur in rare patients with an advanced stage of the disease. The risk of extrahepatic portal vein thrombosis is high. The ætiology of HPS is unclear. Exposure to toxic substances (arsenic or vinyl chloride) or drugs (vitamin A, 6-mercaptopurine), autoimmune and connective tissue diseases, systemic or intraabdominal infections, and clotting abnormalities have been incriminated. A genetic background has been suggested. HPS is usually a diagnosis of exclusion. Differential diagnosis from liver cirrhosis is crucial and may be difficult. A large liver biopsy specimen, together with expertise and awareness of the examiner, are requested for optimal diagnosis. Variceal bleeding is the main cause for morbidity and mortality. Treatment of active bleeding and its prophylaxis can follow the recommendations for patients with cirrhosis. In considering splenectomy, the high risk of thrombosis in the portal venous system should be taken into account. Current overallprognosis is good (80% survival at ten years after the diagnosis). Male patients and patients with disease onset before 40 years of age show a poorer prognosis.
'''Hepatoportal sclerosis (HPS)''' is a rare disorder characterized by sclerosis of the intrahepatic portal veins, non-cirrhotic portal hypertension, asymptomatic splenomegaly and recurrent variceal bleeding. Prevalence is unknown. Distribution is worldwide, with many cases reported in Asia. The disease may occur at any age. Both sexes are equally affected. HPS typically manifests with overt splenomegaly with pancytopenia, portal hypertension and mild abnormalities in liver function tests. HPS patients are in good condition, but may present with ruptured esophagogastric varices. Most commonly, the condition is detected in investigating a fortuitous finding of hypersplenism or splenomegaly. Ascites, hepatic encephalopathy and jaundice are uncommon. Main histopathologic findings are periportal fibrosis, occlusion of small portal veins, sclerosis of the portal venous system, and proliferation of small vascular channels within/around portal tracts. The disease is slowly progressive. Liver failure, ascites or encephalopathy may occur in rare patients with an advanced stage of the disease. The risk of extrahepatic portal vein thrombosis is high. The ætiology of HPS is unclear. Exposure to toxic substances (arsenic or vinyl chloride) or drugs (vitamin A, 6-mercaptopurine), autoimmune and connective tissue diseases, systemic or intraabdominal infections, and clotting abnormalities have been incriminated. A genetic background has been suggested. HPS is usually a diagnosis of exclusion. Differential diagnosis from liver cirrhosis is crucial and may be difficult. A large liver biopsy specimen, together with expertise and awareness of the examiner, are requested for optimal diagnosis. Variceal bleeding is the main cause for morbidity and mortality. Treatment of active bleeding and its prophylaxis can follow the recommendations for patients with cirrhosis. In considering splenectomy, the high risk of thrombosis in the portal venous system should be taken into account. Current overallprognosis is good (80% survival at ten years after the diagnosis). Male patients and patients with disease onset before 40 years of age show a poorer prognosis.

Revision as of 06:41, 16 July 2012

WikiDoc Resources for Obliterative portal venopathy

Articles

Most recent articles on Obliterative portal venopathy

Most cited articles on Obliterative portal venopathy

Review articles on Obliterative portal venopathy

Articles on Obliterative portal venopathy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Obliterative portal venopathy

Images of Obliterative portal venopathy

Photos of Obliterative portal venopathy

Podcasts & MP3s on Obliterative portal venopathy

Videos on Obliterative portal venopathy

Evidence Based Medicine

Cochrane Collaboration on Obliterative portal venopathy

Bandolier on Obliterative portal venopathy

TRIP on Obliterative portal venopathy

Clinical Trials

Ongoing Trials on Obliterative portal venopathy at Clinical Trials.gov

Trial results on Obliterative portal venopathy

Clinical Trials on Obliterative portal venopathy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Obliterative portal venopathy

NICE Guidance on Obliterative portal venopathy

NHS PRODIGY Guidance

FDA on Obliterative portal venopathy

CDC on Obliterative portal venopathy

Books

Books on Obliterative portal venopathy

News

Obliterative portal venopathy in the news

Be alerted to news on Obliterative portal venopathy

News trends on Obliterative portal venopathy

Commentary

Blogs on Obliterative portal venopathy

Definitions

Definitions of Obliterative portal venopathy

Patient Resources / Community

Patient resources on Obliterative portal venopathy

Discussion groups on Obliterative portal venopathy

Patient Handouts on Obliterative portal venopathy

Directions to Hospitals Treating Obliterative portal venopathy

Risk calculators and risk factors for Obliterative portal venopathy

Healthcare Provider Resources

Symptoms of Obliterative portal venopathy

Causes & Risk Factors for Obliterative portal venopathy

Diagnostic studies for Obliterative portal venopathy

Treatment of Obliterative portal venopathy

Continuing Medical Education (CME)

CME Programs on Obliterative portal venopathy

International

Obliterative portal venopathy en Espanol

Obliterative portal venopathy en Francais

Business

Obliterative portal venopathy in the Marketplace

Patents on Obliterative portal venopathy

Experimental / Informatics

List of terms related to Obliterative portal venopathy

Hepatoportal sclerosis (HPS) is a rare disorder characterized by sclerosis of the intrahepatic portal veins, non-cirrhotic portal hypertension, asymptomatic splenomegaly and recurrent variceal bleeding. Prevalence is unknown. Distribution is worldwide, with many cases reported in Asia. The disease may occur at any age. Both sexes are equally affected. HPS typically manifests with overt splenomegaly with pancytopenia, portal hypertension and mild abnormalities in liver function tests. HPS patients are in good condition, but may present with ruptured esophagogastric varices. Most commonly, the condition is detected in investigating a fortuitous finding of hypersplenism or splenomegaly. Ascites, hepatic encephalopathy and jaundice are uncommon. Main histopathologic findings are periportal fibrosis, occlusion of small portal veins, sclerosis of the portal venous system, and proliferation of small vascular channels within/around portal tracts. The disease is slowly progressive. Liver failure, ascites or encephalopathy may occur in rare patients with an advanced stage of the disease. The risk of extrahepatic portal vein thrombosis is high. The ætiology of HPS is unclear. Exposure to toxic substances (arsenic or vinyl chloride) or drugs (vitamin A, 6-mercaptopurine), autoimmune and connective tissue diseases, systemic or intraabdominal infections, and clotting abnormalities have been incriminated. A genetic background has been suggested. HPS is usually a diagnosis of exclusion. Differential diagnosis from liver cirrhosis is crucial and may be difficult. A large liver biopsy specimen, together with expertise and awareness of the examiner, are requested for optimal diagnosis. Variceal bleeding is the main cause for morbidity and mortality. Treatment of active bleeding and its prophylaxis can follow the recommendations for patients with cirrhosis. In considering splenectomy, the high risk of thrombosis in the portal venous system should be taken into account. Current overallprognosis is good (80% survival at ten years after the diagnosis). Male patients and patients with disease onset before 40 years of age show a poorer prognosis.